Oxford PharmaGenesis has enjoyed another great year of bringing success for clients. From innovative studies to employee milestones, to a prestigious King’s Award, here is a round-up of our top highlights and most viewed headlines of the year.
Read on to find out what we have been up to in 2023, and if you are looking to work with us, whether as a client or a colleague, get in touch for a chat.
Oxford PharmaGenesis honoured with prestigious King’s Award for Enterprise
In April, we were honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the UK, recognizing the company’s excellence in International Trade.
The King’s Awards celebrate the success of exciting and innovative businesses. This win completed a hat-trick for Oxford PharmaGenesis, having secured the Queen’s Award for Enterprise in 2015 and 2019.
Celebrating five colleagues who have dedicated more than 20 years to Oxford PharmaGenesis
In October, we were thrilled to celebrate five colleagues who have dedicated more than 20 years to Oxford PharmaGenesis!
All five colleagues have spent more than two decades working on client services, from medical affairs to patient engagement and beyond.
We asked them to share their thoughts, wisdom and experiences.
Here’s what they said.
Medical Affairs Communications Team of the Year: Oxford PharmaGenesis colleagues win prestigious 2023 PharmaTimes award
November saw Oxford PharmaGenesis colleagues named Medical Affairs Communications Team of the Year.
Announced at a special awards ceremony, the PharmaTimes award recognizes our team’s success in a unique annual competition which took place a month before. The competition involved an intense but fun team-building challenge to prepare a response to a communications brief from a fictional pharmaceutical brand.
How did our team impress the judging panel? Find out here.
Pharmaceutical companies reduce own greenhouse gas emissions, but action on supply chains needed
In February, a new study published in the International Journal of Environmental Research and Public Health revealed the climate change targets of the 20 leading global pharmaceutical companies – and how they are reporting on and reducing their greenhouse gas emissions. The study was co-authored by DPhil student Dr Amy Booth (University of Oxford) and Oxford PharmaGenesis CEO Dr Chris Winchester.
The study was understood to be the first to examine the climate change targets and emission reduction strategies of leading pharmaceutical companies.
A Great Place to Work® for 2022–2023: Oxford PharmaGenesis awarded certification for another year running
In February, Oxford PharmaGenesis secured Great Place to Work® accreditation for a third consecutive year in the UK and a seventh consecutive year in the USA.
Considered the ‘gold standard’ of employer awards, Great Place to Work® accreditation is based solely on the views of employees. It takes into account the employee experience and the leadership and HR practices that create the organization’s workplace culture.
The MM+M Agency 100 report: Oxford PharmaGenesis is recognized as an industry leader for the third year running
We enjoyed another award hat-trick in June, as media brand Medical Marketing and Media (MM+M) listed Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.
The Agency 100 is the annual definitive ‘who’s who’ ranking of the healthcare sector’s top marketing firms in North America. A key indicator of the sector’s health, it spotlights the most accomplished players in a competitive and fast-evolving field.
MS Brain Health highly commended for PRIME Award for Sustained Excellence in recognition of the impact of its policy recommendations
In November, Oxford PharmaGenesis, Oxford Health Policy Forum and MS Australia celebrated the shortlisting of MS Brain Health for a PRIME Award for Sustained Excellence. They were incredibly proud to be highly commended at the award ceremony in Sydney, Australia.
The PRIME Awards recognize and celebrate excellence within healthcare communications and the Australian pharmaceutical and life sciences industry.
Championing diversity and inclusion: Oxford PharmaGenesis proud to be a finalist at the 2023 Communiqué Awards
Oxford PharmaGenesis was proud to be a finalist for the prestigious 2023 Communiqué Leadership Award for Action on Workforce Diversity and Inclusion. The awards ceremony took place in July at the Dorchester Hotel, London, UK.
The Communiqué Awards celebrate excellence within the healthcare communications industry in the UK and Europe.
Celebrating 5 years of working with Asia-Pacific clients through our Melbourne office
With a strong biotech and pharmaceutical sector, Melbourne, Australia was the ideal city in which to establish an Oxford PharmaGenesis base for Asia-Pacific (APAC).
Since it opened in 2018 with just one employee, the Melbourne office has seen brilliant growth and success with APAC clients. We celebrated its fifth birthday in April.
Why did it go viral? An informatics-based case study of exaggerated language in news and social media
In 2023 we shared results of our study looking at the viral spread of a science news story.
The story was about a new treatment for a specific type of rectal cancer. Despite involving only 12 patients, the study – presented and published in June 2022 – led to a surprising amount of news and social media interest.
We used news monitoring software and artificial intelligence tools to seek insights into the first articles.
We’re looking forward to celebrating more achievements for our company, clients and colleagues in 2024!